50,000 Shares in Alector, Inc. (NASDAQ:ALEC) Purchased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Alector, Inc. (NASDAQ:ALEC) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,000 shares of the company’s stock, valued at approximately $94,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.05% of Alector at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Millennium Management LLC raised its holdings in shares of Alector by 45.8% during the 4th quarter. Millennium Management LLC now owns 74,685 shares of the company’s stock worth $141,000 after acquiring an additional 23,467 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its position in Alector by 4.1% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,059,691 shares of the company’s stock worth $2,003,000 after purchasing an additional 42,004 shares during the last quarter. D. E. Shaw & Co. Inc. increased its position in Alector by 93.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 368,977 shares of the company’s stock worth $697,000 after purchasing an additional 177,985 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in Alector by 1.1% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 1,066,962 shares of the company’s stock valued at $2,017,000 after purchasing an additional 11,770 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Alector by 723.0% during the fourth quarter. BNP Paribas Financial Markets now owns 165,589 shares of the company’s stock valued at $313,000 after purchasing an additional 145,469 shares during the last quarter. Hedge funds and other institutional investors own 85.83% of the company’s stock.

Alector Trading Down 3.6%

Alector stock opened at $1.07 on Thursday. Alector, Inc. has a 12-month low of $0.87 and a 12-month high of $6.78. The firm has a 50-day moving average price of $1.16 and a 200-day moving average price of $2.05. The firm has a market capitalization of $106.99 million, a PE ratio of -0.63 and a beta of 0.76.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The company had revenue of $54.24 million for the quarter, compared to analyst estimates of $20.41 million. As a group, sell-side analysts predict that Alector, Inc. will post -1.88 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HC Wainwright boosted their target price on shares of Alector from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Morgan Stanley reiterated an “underweight” rating and issued a $1.50 price target (down previously from $3.00) on shares of Alector in a research report on Friday, March 7th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $4.00.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.